Coverage strategy · from the 250-topic plan
The denial letter, translated: what each rejection reason actually means — and the counter each one invites
A denial letter is two documents wearing one envelope: a rejection, and — read correctly — the specification sheet for the appeal that beats it, because insurers must state their reason, and each reason has a distinct counter. The translation table: “not medically necessary” = the criteria weren't documented (most winnable; the anatomy plus your baselines are the counter); “step therapy required” = try-and-fail something first (counter: document the trying, or the contraindication to it); “non-formulary” = the drug isn't on the list (counter: the formulary-exception process); “quantity/dose limits” = a titration mismatch (counter: the label's own schedule); and “plan exclusion” = the one wall appeals rarely climb, because it's plan design — the employer lane's territory, not the appeal desk's. Deadlines, the external-review escalator, and the scripts — below.
Reading the letter's anatomy
Every denial contains, by regulation, the load-bearing parts: the specific reason (the code and phrase this file translates), the criteria applied (often naming the exact clinical policy — your appeal's target document, frequently searchable online in full), your appeal rights and deadlines (internal levels, then external review), and the submission mechanics. The reading discipline: pull the clinical-policy document the letter cites, because it lists — in checkbox form — precisely what evidence would have approved you, converting the appeal from persuasion into form-filling with receipts. File the letter itself in the packet; it's evidence now.
The five reasons, each with its counter
“Not medically necessary.” Translation: the submission didn't check the policy's boxes — BMI thresholds, comorbidity documentation, prior-attempt history. Counter: the checklist itself — your baseline labs, diagnosis codes on record (apnea per the OSA file and prediabetes are heavyweight boxes), and a clinician letter mapping each criterion to your chart line-by-line, per the anatomy. This is the most-overturned denial category in the building. “Step therapy required.” Translation: the plan wants cheaper attempts first. Counter: document that the steps happened (any supervised program, prior medications) — or that they're contraindicated or previously failed, which most policies accept as bypass; your trail is the receipts drawer. “Non-formulary.” Translation: the drug isn't on the list, but the category may be covered. Counter: the formulary-exception request — a distinct process the letter must describe — arguing the formulary alternative is inappropriate for you; where the plan covers Wegovy but not Zepbound (or the reverse), the head-to-head file and your tolerability history are the exception's spine. “Quantity or dose limits.” Translation: the claim exceeded the plan's per-fill math — often a titration artifact. Counter: the label's own dosing schedule attached; these resolve fast because the insurer's limit and the manufacturer's label are having a paperwork disagreement you didn't cause. “Plan exclusion.” Translation: weight-management drugs aren't a covered benefit at all. Counter: mostly none at the appeal desk — see below.
Deadlines and the escalator
The machinery runs on clocks: internal appeals carry filing windows (commonly measured in months — your letter states yours), plans owe decisions within regulated timeframes, and expedited lanes exist where delay threatens health. Lose internally and the external review escalator engages — an independent reviewer, binding on the plan, free to you, and statistically kinder to patients than the internal desk. The sequencing rule: never skip a level (external review requires exhausting internal), never miss a window (calendar the deadline the day the letter arrives), and never send an appeal unaccompanied — the clinician letter, the labs, the policy-checklist mapping travel together or the appeal travels alone.
The exclusion wall, honestly
When the reason is a categorical benefit exclusion, the appeal desk is the wrong building: exclusions are plan-design decisions — for self-funded plans, literally your employer's authorship — and the productive moves are the employer lane's (the benefits request timed to design season, the wellness-program question) plus two narrower doors: the same-molecule, different-indication reality (plans excluding weight coverage often cover the molecules for diabetes — a legitimate matter of your actual diagnoses and your prescriber's judgment, never of creative coding) and comorbidity-indication routes (the OSA and cardiovascular indications changed some plans' math). Meanwhile the bridge stays priced: the audited $119–$139 cash floors with HSA/FSA treatment, so the coverage campaign never holds therapy hostage. The bridge while you appeal ↗
FAQ
What does “not medically necessary” mean on a GLP-1 denial?
The submission didn't document the policy's criteria — pull the cited clinical policy, map your labs and diagnoses to its checklist in a clinician letter, and appeal; it's the most-overturned category.
Can I beat a step-therapy denial?
Often — document prior attempts, or contraindication/failure of the required steps, which most policies accept as bypass.
What if my plan excludes weight-loss drugs entirely?
Appeals rarely climb design exclusions — work the employer lane, check the diabetes-indication and comorbidity routes with your prescriber, and bridge on the audited cash floors meanwhile.
What is external review?
An independent, binding, free reviewer available after internal appeals exhaust — statistically friendlier to patients, reached only by exhausting internal levels on time.
Sources
- Denial-notice content requirements; internal-appeal and external-review frameworks.
- Plan clinical-policy documents (criteria checklists).
- Companion files: appeal anatomy, employer lane, lab panel, paper trail.